CA2231045A1 - Procede de production de phages vecteurs de presentation - Google Patents

Procede de production de phages vecteurs de presentation Download PDF

Info

Publication number
CA2231045A1
CA2231045A1 CA002231045A CA2231045A CA2231045A1 CA 2231045 A1 CA2231045 A1 CA 2231045A1 CA 002231045 A CA002231045 A CA 002231045A CA 2231045 A CA2231045 A CA 2231045A CA 2231045 A1 CA2231045 A1 CA 2231045A1
Authority
CA
Canada
Prior art keywords
sequence
recombination
vector
recombination site
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002231045A
Other languages
English (en)
Inventor
Nicholas John Hawkins
David Zahra
Tony Vancov
Robyn Lynne Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRC for Biopharmaceutical Research Pty Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2231045A1 publication Critical patent/CA2231045A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé de production d'un phage vecteur de présentation qui consiste à provoquer ou à permettre la recombinaison entre (i) un premier vecteur qui inclut une séquence codant une première chaîne polypeptidique d'un élément spécifique d'une paire de liaison, et (ii) un second phage vecteur qui inclut une séquence codant une cre recombinase fonctionnellement liée à une séquence témoin qui permet l'expression de la Cre recombinase et une séquence codant une seconde chaîne polypeptidique d'un élément spécifique d'une paire de liaison, l'événement de recombinaison engendrant un phage vecteur de recombinaison dans lequel l'expression de la Cre recombinase est sensiblement inhibée. La présente invention concerne également un phage vecteur qui inclut une séquence nucléotidique codant une séquence promotrice, un premier site de recombinaison, en aval et à proximité de la séquence promotrice, et un cadre de lecture ouvert pour cre recombinase, située en aval et à proximité du site de recombinaison, de telle sorte que le promoteur dirige l'expression de la Cre recombinase.
CA002231045A 1995-09-05 1996-09-05 Procede de production de phages vecteurs de presentation Abandoned CA2231045A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPN5239A AUPN523995A0 (en) 1995-09-05 1995-09-05 Method for producing phage display vectors
AUPN5239 1995-09-05

Publications (1)

Publication Number Publication Date
CA2231045A1 true CA2231045A1 (fr) 1997-03-13

Family

ID=3789568

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002231045A Abandoned CA2231045A1 (fr) 1995-09-05 1996-09-05 Procede de production de phages vecteurs de presentation

Country Status (5)

Country Link
EP (1) EP0850309A1 (fr)
JP (1) JPH10511001A (fr)
AU (1) AUPN523995A0 (fr)
CA (1) CA2231045A1 (fr)
WO (1) WO1997009436A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US6720140B1 (en) 1995-06-07 2004-04-13 Invitrogen Corporation Recombinational cloning using engineered recombination sites
DE69623057T2 (de) 1995-06-07 2003-03-27 Invitrogen Corp., Carlsbad Rekombinatorische klonierung in vitro unter verwendung genmanipulierter rekombinationsorte
US6051409A (en) 1995-09-25 2000-04-18 Novartis Finance Corporation Method for achieving integration of exogenous DNA delivered by non-biological means to plant cells
US5851808A (en) 1997-02-28 1998-12-22 Baylor College Of Medicine Rapid subcloning using site-specific recombination
ATE341621T1 (de) * 1997-10-24 2006-10-15 Invitrogen Corp Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US7102055B1 (en) 1997-11-18 2006-09-05 Pioneer Hi-Bred International, Inc. Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
NZ504300A (en) * 1997-11-18 2002-06-28 Pioneer Hi Bred Int A method for directional stable transformation of eukaryotic cells using non-identical recombination sites
DE69841438D1 (de) 1997-11-18 2010-02-25 Pioneer Hi Bred Int Mobilisierung eines viralen genoms aus t-dna durch ortsspezifische rekombinationssysteme
ATE317440T1 (de) 1997-11-18 2006-02-15 Pioneer Hi Bred Int Neuartige methode zur integration von fremd-dna ins eukaryotische genom
WO2000006717A2 (fr) 1998-07-27 2000-02-10 Genentech, Inc. Efficacite de transformation amelioree de l'expression a la surface des phages par modification d'une proteine de coque
NZ525134A (en) 1999-03-02 2004-09-24 Invitrogen Corp Compositions and methods for use in recombinational cloning of nucleic acids
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US7560622B2 (en) 2000-10-06 2009-07-14 Pioneer Hi-Bred International, Inc. Methods and compositions relating to the generation of partially transgenic organisms
US20030235814A1 (en) * 2002-06-19 2003-12-25 Los Alamos National Laboratory Compositions and methods for selecting open reading frames
EP1697534B1 (fr) 2003-12-01 2010-06-02 Life Technologies Corporation Molecule d'acide nucleique contenant des sites de recombinaison et leurs procedes d'utilisation
ATE523603T1 (de) 2008-11-21 2011-09-15 Chimera Biotec Gmbh Konjugatkomplexe zum analytnachweis
US9712606B2 (en) * 2014-05-21 2017-07-18 Nasdaq Technology Ab Efficient and reliable host distribution of totally ordered global state
BR112019009316A2 (pt) 2016-12-26 2019-08-06 Japan Chem Res anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie.
AU2017385274B2 (en) 2016-12-26 2024-02-22 Jcr Pharmaceuticals Co., Ltd. Fusion protein including BDNF
EP3750921A4 (fr) 2018-02-05 2021-11-10 JCR Pharmaceuticals Co., Ltd. Procédé d'administration d'un médicament à un muscle
MX2024005968A (es) 2021-11-19 2024-08-06 Jcr Pharmaceuticals Co Ltd Peptido que tiene afinidad por el receptor de transferrina humano.

Also Published As

Publication number Publication date
AUPN523995A0 (en) 1995-09-28
WO1997009436A1 (fr) 1997-03-13
JPH10511001A (ja) 1998-10-27
EP0850309A1 (fr) 1998-07-01

Similar Documents

Publication Publication Date Title
CA2231045A1 (fr) Procede de production de phages vecteurs de presentation
AU690171B2 (en) Recombinant binding proteins and peptides
Cutting et al. Regulatory studies on the promoter for a gene governing synthesis and assembly of the spore coat in Bacillus subtilis
Podbielski et al. Novel series of plasmid vectors for gene inactivation and expression analysis in group A streptococci (GAS)
US6143527A (en) Chain reaction cloning using a bridging oligonucleotide and DNA ligase
US6159690A (en) Method for in vitro molecular evolution of protein function using exonuclease and amplification
EP1366176B1 (fr) Genes synthetiques et plasmides bacteriens depourvus de cpg
EP1487982B1 (fr) MISE AU POINT DE NOUVELLES SOUCHES A GENOME REDUIT A L'AIDE D'UN SYSTEME D'EXCISION Cre/loxp A COUPLAGE PAR Tn5
US20080268520A1 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
US20040092016A1 (en) Enhanced homologous recombination mediated by lambda recombination proteins
DE10053224A1 (de) Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
JPH11507236A (ja) 操作された組換え部位を使用する組換えクローニング
JP2004187694A (ja) 反復的選択および組換えにより所望の特徴を有するポリヌクレオチドを作製する方法
WO1996040722A1 (fr) Expression chromosomique de genes heterologues dans des cellules bacteriennes
JP5149476B2 (ja) ペプチドの多種多様なファミリーのメンバーとしての、遺伝的パッケージの提示ライブラリーを構築する方法
Murphy et al. Molecular cloning and characterization of the recA gene from the cyanobacterium Synechococcus sp. strain PCC 7002
CA2223519A1 (fr) Procedes d'evaluation de cibles antimicrobiennes
US6673567B2 (en) Method of determination of gene function
Zahra et al. Selectable in-vivo recombination to increase antibody library size—an improved phage display vector system
WO2000029000A9 (fr) Compositions et methodes de clonage recombinatoire de molecules d'acide nucleique
JPH0568599A (ja) 遺伝子工学的に作られた抗体
WO1998037175A1 (fr) Procede servant a construire des vecteurs de recombinaison homologue pour une mutagenese dirigee
CZ152197A3 (en) Process for preparing nisine variant
AU616945B2 (en) Modified dna sequences coding for mutant endotoxins of bacillus thuringiensis
CA1321563C (fr) Promoteur inductible par la lumiere

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued